Payer Policy

Florida Blue Prior Authorization Guide 2026: Forms, Phone Numbers, Step Therapy & Appeals

How to get specialty drugs approved by Florida Blue (BCBS Florida) in 2026: PA submission via Availity, Prime Therapeutics pharmacy PA, Florida step therapy override rights, and the appeal process.

RxCheckUp Clinical Team · 2026-10-02 · 13 min read

Who Is Florida Blue — and Why Its Prior Authorization Rules Matter

Florida Blue is the Blue Cross Blue Shield licensee for Florida and the largest health insurer in the state, covering commercial employer groups, individual ACA marketplace members, Medicare Advantage and Part D enrollees, and Federal Employee Program members. Because Florida has one of the largest ACA marketplaces in the country, a significant share of Florida Blue members sit on individual plans with narrower formularies and tighter utilization management.

For prescribers, that means a large volume of specialty prescriptions in Florida route through Florida Blue's prior authorization (PA) process. Knowing which benefit a drug falls under, which policy applies, and which Florida-specific protections are available is the difference between a same-week approval and a month of resubmissions.

One important caveat before you start: plan type determines the rules. Fully insured Florida Blue plans are regulated by Florida law, while self-funded employer plans administered by Florida Blue are governed by federal ERISA rules and may use custom formularies. Medicare Advantage plans follow CMS rules. Always confirm the plan type on the member ID card or eligibility response first.

Pharmacy Benefit vs. Medical Benefit: Where to Send the Request

Florida Blue splits drug prior authorization by benefit. Self-administered drugs dispensed at a retail or specialty pharmacy — oral oncology agents, GLP-1 receptor agonists, self-injected biologics like Humira, Dupixent, and Skyrizi — are generally managed on the pharmacy benefit, with Prime Therapeutics serving as the pharmacy benefit manager for most Florida Blue plans.

Clinician-administered drugs billed with HCPCS J-codes — infusions such as Ocrevus, Entyvio IV, Keytruda, and Tysabri — are managed on the medical benefit and reviewed against Florida Blue Medical Coverage Guidelines. Sending a medical-benefit drug through the pharmacy channel (or vice versa) is one of the most common causes of "not a covered benefit" denials.

✓ Pharmacy-benefit drugs: submit via electronic PA (CoverMyMeds or Surescripts ePA in the EHR) or Prime Therapeutics' PA channels
✓ Medical-benefit drugs: submit through Availity Essentials, Florida Blue's provider portal for authorizations
✓ Medicare Advantage: Part B drugs go through the medical PA process; Part D drugs go through the Part D coverage determination process
✓ When in doubt, check the plan formulary and the Medical Coverage Guideline for the drug before submitting

Florida Blue Contact Information for Prior Authorization

Contact details vary by product line and change periodically, so verify against the member ID card and the Florida Blue provider site before submitting. The commonly used provider channels are:

✓ Provider PA phone: 1-800-955-5692
✓ PA fax: 1-904-565-6637
✓ Member appeals mailing address: Florida Blue, Attn: Member Appeals, PO Box 44232, Jacksonville, FL 32231
✓ Provider portal: Availity Essentials (floridablue.com/providers)
✓ Medical Coverage Guidelines: floridablue.com/providers/medical-pharmacy-info/medical-policies

Step-by-Step: Submitting a Florida Blue Prior Authorization

Step 1 — Identify the governing policy. Look up the Florida Blue Medical Coverage Guideline (medical benefit) or the Prime Therapeutics clinical criteria (pharmacy benefit) for the drug. Note the guideline number; citing it in your letter signals to the reviewer that you are addressing their own criteria.

Step 2 — Map the patient to every criterion. Build a checklist from the policy: diagnosis and ICD-10 code, severity measures, required prior therapies, labs, specialist requirements, and quantity or dosing limits. Most denials happen because one criterion was silently skipped.

Step 3 — Document prior therapies precisely. List each prior drug with dose, start and stop dates, and the specific reason it was stopped (inadequate response with objective measures, adverse event, or contraindication). "Failed methotrexate" is weak; "methotrexate 20 mg weekly 01/2025–07/2025, discontinued for persistent DAS28-CRP 5.4 and ALT 3x ULN" is strong.

Step 4 — Attach a Letter of Medical Necessity. The LMN should front-load the request, cite the guideline number, address each criterion in order, and reference FDA labeling and specialty society guidelines.

Step 5 — Request expedited review when appropriate. If waiting for a standard decision could seriously jeopardize the patient's health, mark the request urgent and include a short clinical justification.

Florida Step Therapy Protections You Should Use

Florida law gives prescribers specific tools on fully insured, state-regulated plans. Florida Statutes §627.42393 requires insurers that use step therapy protocols to offer a step therapy override (exception) process, and §627.42392 sets standards for prescription drug prior authorization, including a standardized PA form. These protections do not apply to self-funded ERISA plans.

An override request is strongest when it fits one of the recognized exception scenarios. Name the scenario explicitly in your letter rather than leaving the reviewer to infer it.

✓ The required step drug is contraindicated or likely to cause an adverse reaction for this patient
✓ The patient already tried the required drug (or a drug in the same class/mechanism) under this or a previous plan and it was ineffective or not tolerated
✓ The patient is stable on the prescribed drug, and switching would risk destabilizing a controlled condition
✓ The required drug is expected to be ineffective based on the patient's known clinical characteristics

Typical Florida Blue Criteria by Drug Class

Exact criteria depend on the plan and policy version, but recurring patterns in Florida Blue reviews include:

✓ Rheumatoid arthritis biologics and JAK inhibitors: trial of conventional DMARDs (often two, including methotrexate) and TB screening before a biologic; preferred biologics or biosimilars before non-preferred agents
✓ Psoriasis biologics: documented BSA/PASI, plus phototherapy and/or a conventional systemic agent before a biologic
✓ Atopic dermatitis: topical corticosteroid and calcineurin inhibitor trials with baseline EASI/IGA before Dupixent; a biologic trial before oral JAK inhibitors
✓ GLP-1 receptor agonists: type 2 diabetes diagnosis with A1c for Ozempic/Mounjaro; weight-management coverage (Wegovy, Zepbound, Saxenda) depends on whether the group or plan includes an anti-obesity benefit
✓ Oral oncology: biomarker or companion diagnostic report, line of therapy, and NCCN category of evidence
✓ Infused biologics: site-of-care review that may steer stable patients from hospital outpatient infusion to home or office infusion

Top Reasons Florida Blue Denies Prior Authorization

In our analysis of payer denial patterns, Florida Blue denials cluster around a handful of fixable issues:

✓ Medical Coverage Guideline criteria not met or not addressed point-by-point
✓ Step therapy not completed and no override scenario documented
✓ Non-preferred formulary status when a preferred biosimilar or alternative exists
✓ Site-of-care restriction for infused drugs
✓ Missing severity scores, labs, or companion diagnostic results
✓ Request sent to the wrong benefit (pharmacy vs. medical)

How to Appeal a Florida Blue Denial

Start by reading the denial letter for the exact reason and the policy cited. If the denial turned on a clinical judgment, request a peer-to-peer review with the Florida Blue medical director — many denials are reversed in a 10-minute conversation when the prescriber walks through missing context.

For commercial plans, members (or prescribers acting on their behalf) generally have 180 days from the denial to file an internal appeal. Standard pre-service appeals are typically decided within about 15 to 30 days; expedited appeals for urgent situations must be decided within 72 hours. Include a rebuttal letter that quotes the denial reason and answers it directly, plus new supporting documentation.

If the internal appeal is upheld, the member can request an independent external review. The final denial letter explains the external review route and deadline for that plan type.

For Florida Blue Medicare Advantage and Part D plans, CMS timelines apply: Part D coverage determinations are decided within 72 hours (24 hours expedited), and redeterminations must be requested within 65 days of the denial notice.

Checklist: A Florida Blue PA Packet That Gets Approved

Before you hit submit, confirm the packet includes:

✓ Correct benefit channel (Availity for medical, ePA/Prime for pharmacy)
✓ Florida Blue guideline or criteria reference in the letter
✓ ICD-10 code with full specificity and baseline severity scores
✓ Dated prior therapy history with objective reasons for discontinuation
✓ Required labs, screenings, and diagnostic reports attached
✓ Named step therapy exception scenario under Florida law (fully insured plans)
✓ Specific request: drug, dose, frequency, route, and duration

How RxCheckUp Helps With Florida Blue Prior Authorizations

RxCheckUp maps each request to the relevant Florida Blue and Prime Therapeutics criteria, flags missing documentation before submission, and generates a Letter of Medical Necessity that addresses each criterion in order with linked clinical evidence. For denials, it drafts a targeted appeal that quotes the denial reason and cites the applicable Florida step therapy protections.